))
Episode 7: Clinical Trials and Drug Development with Ken Getz
Manage episode 410005710 series 3552382
Sisällön tarjoaa Michael Pietrack. Michael Pietrack tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Welcome back to the Pharmaverse!!
In this episode, host Michael Pietrack interviews Ken Getz, an expert in drug development and a professor at Tufts School of Medicine. They discuss various topics related to clinical trials and drug development, including managing complexity, reducing costs, the impact of AI, challenges in patient enrollment and retention, high failure rates in phase III trials, and the impact of the pandemic on clinical trials. Ken also talks about the work of the Center for Information and Study of Clinical Research Participation (CISCRIP) and how listeners can support their cause. Listen in to learn about Clinical Trials and Drug Development from Ken!
Takeaways:
💊Managing the growing complexity of drug development is crucial for optimizing the process.
💉Reducing drug development costs is a challenge, with factors such as patient recruitment and retention contributing to high expenses.
⚙AI has the potential to reduce costs and improve various aspects of drug development, including patient identification and adverse event prediction.
👨⚕️Challenges in patient enrollment and retention, as well as high failure rates in phase III trials, impact the success of drug development.
🏥The COVID-19 pandemic has affected clinical trials, leading to delays and changes in enrollment.
🤝Supporting organizations like the Center for Information and Study of 🖐Clinical Research Participation (CISCRIP) can help educate the public and improve patient engagement in clinical research.
Sound Bites
Chapters
00:00
Introduction to Ken Getz
01:01
Ken Getz's Background and Involvement in Clinical Trials
03:13
Managing the Growing Complexity of Drug Development
05:11
Reducing Drug Development Costs
07:51
The Impact of AI on Drug Development
13:25
Challenges in Patient Enrollment and Retention
16:01
High Failure Rates in Phase III Trials
19:33
Collaborating with Tufts CSDD
21:48
The Impact of the Pandemic on Clinical Trials
26:44
Supporting the Center for Information and Study of Clinical Research Participation (CISCRIP)
29:08
Closing Remarks and Gratitude
16 jaksoa
Jaa
